Laurus Labs Limited (NSE:LAURUSLABS)
India · Delayed Price · Currency is INR | Market Cap | 973.64B +105.9% |
| Revenue (ttm) | 72.70B +22.6% |
| Net Income | 10.93B +114.9% |
| EPS | 20.23 +114.1% |
| Shares Out | 540.31M |
| PE Ratio | 89.08 |
| Forward PE | 69.33 |
| Dividend | 2.40 (0.13%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 2,894,133 |
| Open | 1,800.00 |
| Previous Close | 1,802.00 |
| Day's Range | 1,790.00 - 1,810.80 |
| 52-Week Range | 823.10 - 1,870.80 |
| Beta | 0.36 |
| Analysts | Hold |
| Price Target | 1,486.29 (-17.34%) |
| Earnings Date | Oct 28, 2026 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug ... [Read more]
Financial Performance
In fiscal year 2026, Laurus Labs's revenue was 68.13 billion, an increase of 22.67% compared to the previous year's 55.54 billion. Earnings were 8.89 billion, an increase of 148.04%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for LAURUSLABS stock is "Hold." The 12-month stock price target is ₹1,486, which is a decrease of -17.34% from the latest price.
News
Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s
Laurus Labs hits Rs 1 lakh crore market cap as shares rally 115% in a year, overtaking Dr Reddy’s and Aurobindo; Divi’s crosses Rs 2.2 lakh crore.
Laurus Labs Q1 net profit surges 126%
Laurus Labs Q1 FY27 net profit jumps 126% to ₹368 crore; revenue rises 29% to ₹2,026 crore, driven by CDMO growth, affordable medicines and capacity expansion.
Laurus Labs Transcript: Q1 26/27
Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO sales and robust Affordable Medicines performance. Margins expanded, CapEx guidance was raised to meet strong customer demand, and the company remains confident in its transformation strategy and future growth, especially in CDMO and Bio segments.
Laurus Labs Quarterly report: Q1 2027
Laurus Labs has published its Q1 2027 quarterly earnings report on July 24, 2026.
Laurus Labs Slides: Q1 2027
Laurus Labs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 24, 2026.
Laurus Labs announces conclusion of Aruna Bhinge's tenure as independent director
Laurus Labs has announced that the tenure of Mrs. Aruna Bhinge as an Independent Director has concluded as of July 6, 2026. This marks the end of her second term…
Laurus Labs appoints Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as independent directors
Laurus Labs has announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as independent directors for a term of five consecutive years, effective from July 2, 2026.…
Laurus Labs Transcript: AGM 2026
The AGM highlighted robust financial performance, strong CDMO growth, and strategic investments in technology and sustainability. Shareholders approved all resolutions, including dividends and director appointments, while management addressed questions on growth, risks, and future plans.
Nifty rebalancing today: MCX, NTPC, Laurus Labs among top inflow beneficiaries; Bharti Airtel, Eicher Motors face highest outflows
Nifty index rebalancing is set to take place on Monday, June 29, with several stocks expected to witness significant passive fund flows as index adjustments come into effect. According to…
Laurus Labs reports 62.14% export contribution to total turnover in FY 2025-26
Laurus Labs Limited has released its Business Responsibility and Sustainability Report for the financial year 2025-26, highlighting a significant export contribution. The report reveals that exports a...
Laurus Labs allots equity shares worth over Rs 12 crore under ESOP schemes
Laurus Labs has announced the allotment of 3,93,001 equity shares to its employees under various stock option schemes, amounting to a total value of ₹12,40,09,974.50. This allotment was approved by…
Laurus Labs included in Dow Jones Best-in-Class indices for ESG performance
Laurus Labs has achieved a significant milestone by being included in the Dow Jones Best-in-Class (DJ BIC) Indices, marking its debut in this prestigious ranking. This inclusion underscores the compan...
Laurus Labs Transcript: Q4 25/26
FY 2026 delivered 23% revenue growth, 26.8% EBITDA margin, and 148% PAT growth, driven by strong CDMO and generics performance. Major CapEx projects and capacity expansions support continued growth, with robust order books and resilient supply chains.
Laurus Labs Quarterly report: Q4 2026
Laurus Labs has published its Q4 2026 quarterly earnings report on April 30, 2026.
Laurus Labs Slides: Q4 2026
Laurus Labs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Laurus Labs Annual report: Q4 2026
Laurus Labs has published its Q4 2026 annual report on April 30, 2026.
Laurus Labs announces voluntary closure of Laurus Generics GmbH
Laurus Labs has announced the voluntary closure of its step-down wholly owned subsidiary, Laurus Generics GmbH, based in Germany. The decision was approved by the Board of Directors during their…
Laurus Labs approves €9.8 million investment in KRKA Pharma joint venture
Laurus Labs has announced a significant investment in its joint venture, KRKA Pharma Private Limited, amounting to up to €9.8 million. This strategic move, approved by the Board of Directors…
Laurus Labs reports ₹6,813 crore revenue for FY26 with 23% growth
Laurus Labs has announced its financial results for the fiscal year ending March 31, 2026, reporting a revenue of ₹6,813 crore, marking a 23% increase over the previous year. The…
Laurus Labs Q4 Results: Profit rises 19% YoY as margin expands nearly 400 bps
Laurus Labs Limited reported a strong growth in profitability for the quarter ended March 31, 2026, supported by steady revenue expansion and improved operating performance. The company’s revenue from...
Laurus Labs to invest ₹82 crore in joint venture and appoints two new independent directors
Laurus Labs Limited has announced significant strategic developments, including a substantial investment in its joint venture and the appointment of two new independent directors. The company's board ...
Laurus Labs receives creditor approval for composite scheme of arrangement
Laurus Labs has announced that the meetings of unsecured creditors for its subsidiaries, Laurus Synthesis and Sriam Labs, have successfully concluded with approval for the Composite Scheme of Arrangem...
Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65%
The Indian pharmaceutical sector showed mixed movements in early trading, as of approximately 9:51 AM IST on March 24, 2026. The S&P BSE Healthcare Index stood at 41,630.4, reflecting a…
Pharma sector stocks surge today, March 20: Laurus Labs jumps 2.83%, Natco Pharma up 2.67%, Aurobindo Pharma gains 2.42%
The pharmaceutical sector in India showed positive movement on March 20, 2026, during early trading hours. The S&P BSE HEALTHCARE Index stood at 42,149.5, reflecting a gain of 1.1%. This…
Pharma sector stocks fall today, March 19: Biocon down 2.33%, Laurus Labs falls 2.29%, Glenmark Pharma drops 2%
Pharmaceutical stocks in India experienced a decline on March 19, 2026, during early trading hours. Market data as of approximately 9:46 AM IST (BSE) and 9:49 AM IST (NSE) showed…